Go to
JCI Insight
JCI’s Conversations with Giants in Medicine: Daniel Drucker
Dr. Dan Drucker, of the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, and the University of Toronto, is a diabetes treatment pioneer. Drucker’s early work explored the biosynthesis, secretion, and action of glucagon, and he later went on to delineate the novel mechanisms of action of glucagon-like peptides (GLP) 1 and 2. His work on GLP-1 and -2 agonists as well as DPP-4 inhibitors provides the foundation for the largest spectrum of drugs for both gut disorders and type 2 diabetes. Watch the full interview to learn about his early stumbles in the lab and his prediction that his next five to ten years in the lab will be very boring.
Published September 15, 2021, by Ushma S. Neill
Related articles
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)